Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 4/2022

Open Access 01-04-2022 | Autoimmune Pancreatitis | Review

Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2020

Authors: Kazuichi Okazaki, Shigeyuki Kawa, Terumi Kamisawa, Tsukasa Ikeura, Takao Itoi, Tetsuhide Ito, Kazuo Inui, Atsushi Irisawa, Kazushige Uchida, Hirotaka Ohara, Kensuke Kubota, Yuzo Kodama, Kyoko Shimizu, Ryosuke Tonozuka, Takahiro Nakazawa, Takayoshi Nishino, Kenji Notohara, Yasunari Fujinaga, Atsushi Masamune, Hiroshi Yamamoto, Takayuki Watanabe, Toshimasa Nishiyama, Mitsuhiro Kawano, Keiko Shiratori, Tooru Shimosegawa, Yoshifumi Takeyama, Members of the Research Committee for IgG4-related Disease supported by the Ministry of Health, Labour, Welfare of Japan, Japan Pancreas Society

Published in: Journal of Gastroenterology | Issue 4/2022

Login to get access

Abstract

In response to the latest knowledge and the amendment of the Japanese diagnostic criteria for autoimmune pancreatitis (AIP) in 2018, the Japanese consensus guidelines for managing AIP in 2013 were required to be revised. Three committees [the professional committee for developing clinical questions (CQs) and statements by Japanese specialists; the expert panelist committee for rating statements by the modified Delphi method; and the evaluating committee of moderators] were organized. Twenty specialists in AIP extracted the specific clinical statements from a total of 5218 articles (1963–2019) from a search in PubMed and the Cochrane Library. The professional committee made 14, 9, 5, and 11 CQs and statements for the current concept and diagnosis, extra-pancreatic lesions, differential diagnosis, and treatment, respectively. The expert panelists regarded the statements as valid after a two-round modified Delphi approach with individually rating these clinical statements, in which a clinical statement receiving a median score greater than 7 on a 9-point scale from the panel was regarded as valid. After evaluation by the moderators, the amendment of the Japanese consensus guidelines for AIP has been proposed in 2020.
Literature
1.
Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40:1561–8.PubMed
2.
Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344:732–8.PubMed
3.
Japan Pancreas Society. Clinical diagnostic criteria for autoimmune pancreaitis. (In Japanese) Suizo. 2002;17:585–7.
4.
Okazaki K, Kawa S, Kamisawa T, et al. Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal. J Gastroenterol. 2006;41:626–31.PubMedPubMedCentral
5.
Members of the Autoimmune Pancreatitis Diagnostic Criteria Committee, the Research Committee of Intractable Diseases of the Pancreas supported by the Japanese Ministry of Health, Labor and Welfare, and Members of the Autoimmune Pancreatitis Diagnostic Criteria Committee, the Japan Pancreas Sociey. Clinical diagnostic criteria of autoimmune pancreatitis 2006. (In Japanese) Suizo. 2006;21:395–7.
6.
Okazaki K, Kawa S, Kamisawa T, et al. Japanese consensus guidelines for management of autoimmune pancreatitis: I. Concept and diagnosis of autoimmune pancreatitis. J Gastroenterol. 2010;45:249–65.PubMed
7.
Kawa S, Okazaki K, Kamisawa T, et al. Japanese consensus guidelines for management of autoimmune pancreatitis: II. Extrapancreatic lesions, differential diagnosis. J Gastroenterol. 2010;45:355–69.PubMed
8.
Kamisawa T, Okazaki K, Kawa S, et al. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol. 2010;45:471–7.PubMed
9.
Okazaki K, Kawa S, Kamisawa T, et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 I. Concept and diagnosis of autoimmune pancreatitis. J Gastroenterol. 2014;49:567–88.PubMed
10.
Kawa S, Okazaki K, Kamisawa T, et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 II. Extrapancreatic lesions, differential diagnosis. J Gastroenterol. 2014;49:765–84.PubMed
11.
Kamisawa T, Okazaki K, Kawa S, et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol. 2014;49:961–70.PubMed
12.
Fitch K, Bernstein SJ, Aguilar MD, et al. The RAND/UCLA appropriateness method user’s manual. Santa Monica CA: RAND, 2001.
13.
14.
The Japan Pancreas Society, the Research Committee of Intractable Diseases for IgG4-related disease supported by the Japanese Ministry of Health, Labor and Welfare. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2020. (In Japanese) Suizo. 2020;35:465–550.
15.
Masamune A, Kikuta K, Hamada S, et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2016. J Gastroentrol. 2020;55:462–70.
16.
Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the international association of pancreatology. Pancreas. 2011;40:352–8.PubMed
17.
Kubota K, Kamisawa T, Hirano K, et al. Clinical course of type 1 autoimmune pancreatitis patients without steroid treatment: a Japanese multicenter study of 97 patients. J Hepatobiliary Pancreat Sci. 2018;25:223–30.PubMed
18.
Kawa S, Okazaki K, Notohara K, et al. Autoimmune pancreatitis complicated with inflammatory bowel disease and comparative study of type 1 and type 2 autoimmune pancreatitis. J Gastroenterol. 2015;50:805–15.PubMed
19.
Okazaki K, Uchida K, Ohana M, et al. Autoimmune-related pancreatitis is associated with autoantibodies and a Th1/Th2-type cellular immune response. Gastroenterology. 2000;118:573–81.PubMed
20.
Hubers LM, Vos H, Schuurman AR, et al. An-nexin A11 is targeted by IgG4 and IgG1 autoanti-bodies in IgG4-related disease. Gut. 2018;67:728–35.PubMed
21.
Shiokawa M, Kodama Y, Kuriyama K, et al. Pathogenicity of IgG in patients with IgG4-relateddisease. Gut. 2016;65:1322–32.PubMed
22.
Shiokawa M, Kodama Y, Sekiguchi K, et al. Laminin 511 is a target antigen in autoimmune pancreatitis. Sci Transl Med. 2018;10:eaaq0997.
23.
Salah A, Yoshifuji H, Ito S, et al. High expression of galectin-3 in patients with IgG4-related disease: A proteomic approach. Patholog Res Int. 2017;2017:9312142.PubMedPubMedCentral
24.
Perugino CA, AlSalem SB, Mattoo H, et al. Identification of galectin-3 as an autoantigen in patients with IgG4-related disease. J Allergy Clin Immunol. 2019;143:736–45.PubMed
25.
Kanno A, Nishimori I, Masamune A, et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan. Pancreas. 2012;41:835–9.PubMed
26.
Frulloni L, Scattolini C, Katsotourchi AM, et al. Exocrine and endocrine pancreatic function in 21 patients suffering from autoimmune pancreatitis before and after steroid treatment. Pancreatology. 2010;10:129–33.PubMed
27.
Kamisawa T, Egawa N, Inokuma S, et al. Pancreatic endocrine and exocrine function and salivary gland function in autoimmune pancreatitis before and after steroid therapy. Pancreas. 2003;27:235–8.PubMed
28.
Nishino T, Toki F, Oyama H, et al. Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy. Intern Med. 2006;45:497–501.PubMed
29.
Ito T, Nishimori I, Inoue N, et al. Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan. J Gastroenterol. 2007;42(Suppl 18):50–8.PubMed
30.
Ito T, Nakamura T, Fujimori N, Niina Y, Igarashi H, Oono T, et al. Characteristics of pancreatic diabetes in patients with autoimmune pancreatitis. J Dig Dis. 2011;12:210–6.PubMed
31.
Irie H, Honda H, Baba S, Kuroiwa T, Yoshimitsu K, Tajima T, et al. Autoimmune pancreatitis: CT and MR characteristics. AJR Am J Roentgenol. 1998;170:1323–7.PubMed
32.
Kamisawa T, Egawa N, Nakajima H, et al. Comparison of radiological and histological findings in autoimmune pancreatitis. Hepatogastroenterol. 2006;53:953–6.
33.
Muraki T, Ozaki Y, Hamano H, et al. Ultrasonographic diagnosis of autoimmune pancreatitis. Biliary Tract Pancreas. 2005;26:711–6.
34.
Takahashi M, Fujinaga Y, Notohara K, et al. Diagnostic imaging guide for autoimmune pancreatitis. Jpn J Radiol. 2020;38:591–612.PubMed
35.
Kawa S, Kamisawa T, Notohara K, et al. Japanese clinical diagnostic criteria for autoimmune pancreatitis, 2018: revision of japanese clinical diagnostic criteria for autoimmune pancreatitis, 2011. Pancreas. 2020;49:e13-14.PubMed
36.
Kamisawa T, Tu Y, Egawa N, et al. Can MRCP replace ERCP for the diagnosis of autoimmune pancreatitis? Abdom Imaging. 2009;34:381–4.PubMed
37.
Isoda H, Kataoka M, Maetani Y, et al. MRCP imaging at 3.0 T vs 1.5 T: preliminary experience in healthy volunteers. J Magn Reson Imaging. 2007;25:1000–6.PubMed
38.
Yanagisawa S, Fujinaga Y, Watanabe T, et al. Usefulness of three-dimensional magnetic resonance cholangiopancreatography with partial maximum intensity projection for diagnosing autoimmune pancreatitis. Pancreatology. 2017;17:567–71.PubMed
39.
Saegusa H, Momose M, Kawa S, et al. Hilar and pancreatic gallium-67 accumulation is characteristic feature of autoimmune pancreatitis. Pancreas. 2003;27:20–5.PubMed
40.
Ozaki Y, Oguchi K, Hamano H, et al. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastroenterol. 2008;43:144–51.PubMed
41.
Sato M, Okumura T, Shioyama Y, et al. Extrapancreatic F-18 FDG accumulation in autoimmune pancreatitis. Ann Nucl Med. 2008;22:215–9.PubMed
42.
Nishimori I, Kohsaki T, Onishi S, et al. IgG4-related autoimmune prostatitis: two cases with or without autoimmune pancreatitis. Intern Med. 2007;46:1983–9.PubMed
43.
Matsubayashi H, Furukawa H, Maeda A, et al. Usefulness of positron emission tomography in the evaluation of distribution and activity of systemic lesions associated with autoimmune pancreatitis. Pancreatology. 2009;9:694–9.PubMed
44.
Shigekawa M, Yamao K, Sawaki A, et al. Is (18)F-fluorodeoxyglucose positron emission tomography meaningful for estimating the efficacy of corticosteroid therapy in patients with autoimmune pancreatitis? J Hepatobiliary Pancreat Surg. 2009;17:269–74.
45.
Toki F, Kozu T, Oi I. An usual type of chronic pancreatitis showing diffuse narrowing of the entire main pancreatic duct on ERCP. A report of four cases. Endoscopy. 1992;24:640.
46.
Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnorrmality; proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40:1561–7.PubMed
47.
Wakabayshi T, Kawamura Y, Satomura Y, et al. Clinical and imaging features of autoimmune pancreatitis with focal pancreatic swelling or mass formation; comparison with so-called tumor-forming paancreatitis and pancreatic cancer. Am J Gastroenterol. 2003;98:2679–87.
48.
Nakazawa T, Ohara H, Sano H, et al. Difficulty in diagnosing autoimmune pancreatitis. Gastrointest Endosc. 2007;65:99–108.PubMed
49.
Nishino T, Oyama H, Toki F, et al. Differentiation between autoimmune pancreatitis and pancreatic carcinoma based on endoscopic retrograde cholangiopancreatography findings. J Gastroenterol. 2010;45:988–96.PubMed
50.
Kamisawa T, Ohara H, Kim MH, et al. Role of endoscopy in diagnosis of autoimmune pancreatitis and immunoglobulin G4- related sclerosing cholangitis. Dig Endosc. 2014;26:627–35.PubMed
51.
Kamisawa T, Imai M, Yui Chen P, et al. Strategy for differentiating autoimmune pancreatitis from pancreatic cancer. Pancreas. 2008;37:e62–7.PubMed
52.
Horiuchi A, Kawa S, Hamano H, Hayama M, Ota H, Kiyosawa K. ERCP features in 27 patients with autoimmune pancreatitis. Gastrointest Endosc. 2002;4:494–9.
53.
Nishino T, Toki F, Oyama H, et al. Biliary tract involvement in autoimmune pancreatitis. Pancreas. 2005;30:76–82.PubMed
54.
Nakazawa T, Ohara H, Sano H, et al. Cholangigraphy can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. Gastrointest Endosc. 2004;60:937–44.PubMed
55.
Hirano K, Shiratori Y, Komatsu Y, et al. Involvement of the biliary system in autoimmune pancreatitis: a follow-up study. Clin Gastroenterol Hepatol. 2003;1:453–64.PubMed
56.
Morishima T, Kawashima H, Ohno E, et al. Prospective multicenter study on the usefulness of EUS-guided FNA biopsy for the diagnosis of autoimmune pancreatitis. Gastrointest Endosc. 2016;84:241–8.PubMed
57.
Kanno A, Masamune A, Fujishima F, et al. Diagnosis of autoimmune pancreatitis by EUS-guided FNA using a 22-gauge needle: a prospective multicenter study. Gastrointest Endosc. 2016;84:797–804.PubMed
58.
Kurita A, Yasukawa S, Zen Y, et al. Comparison of a 22-gauge Franseen-tip needle with a 20-gauge forward-bevel needle for the diagnosis of type 1 autoimmune pancreatitis: a prospective, randomized, controlled, multicenter study (COMPAS study). Gastrointest Endosc. 2020;91:373–81.PubMed
59.
60.
Kanno A, Ishida K, Hamada S, et al. Diagnosis of autoimmune pancreatitis by EUS-FNA by using a 22-gauge needle based on the International Consensus Diagnostic Criteria. Gastrointest Endosc. 2012;76:594–602.PubMed
61.
Detlefsen S, Joergensen MT, Mortensen MB. Microscopic findings in EUS-guided fine needle (SharkCore) biopsies with type 1 and type 2 autoimmune pancreatitis. Pathol Int. 2017;67:514–20.PubMed
62.
Cao L, Wang Y, Wang J, et al. The role of EUS-guided fine needle aspiration in autoimmune pancreatitis: a single center prospective study. Scand J Gastroenterol. 2018;53:1604–10.PubMed
63.
Fujinaga Y, Kadoya M, Kawa S, et al. Characteristic findings in images of extra-pancreatic lesions associated with autoimmune pancreatitis. Eur J Radiol. 2009;76:228–38.PubMed
64.
Hamano H, Kawa S, Ochi Y, et al. Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis. Lancet. 2002;359:1403–4.PubMed
65.
66.
Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22:21–30.PubMed
67.
Yamamoto M, Ohara M, Suzuki C, et al. Elevated IgG4 concentrations in serum of patients with Mikulicz’s disease. Scand J Rheumatol. 2004;33:432–3.PubMed
68.
Yamamoto M, Harada S, Ohara M, et al. Clinical and pathological differences between Mikulicz’s disease and Sjogren’s syndrome. Rheumatology (Oxford). 2005;44:227–34.
69.
Yamamoto M, Takahashi H, Ohara M, et al. A new conceptualization for Mikulicz’s disease as an IgG4-related plasmacytic disease. Mod Rheumatol. 2006;16:335–40.PubMedPubMedCentral
70.
Hamano H, Arakura N, Muraki T, et al. Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis. J Gastroenterol. 2006;41:1197–205.PubMed
71.
Kubota K, Wada T, Kato S, et al. Highly active state of autoimmune pancreatitis with mikulicz disease. Pancreas. 2010;39:e6-10.PubMed
72.
Ogoshi T, Kido T, Yatera K, et al. Incidence and outcome of lung involvement in IgG4-related autoimmune pancreatitis. Respirology. 2015;20:1142–4.PubMed
73.
Hirano K, Kawabe T, Komatsu Y, et al. High-rate pulmonary involvement in autoimmune pancreatitis. Intern Med J. 2006;36:58–61.PubMed
74.
Vlachou PA, Khalili K, Jang HJ, et al. IgG4-related sclerosing disease autoimmune pancreatitis and extrapancreatic manifestations. Radiographics. 2011;31:1379–402.PubMed
75.
Matsui S, Hebisawa A, Sakai F, et al. Immunoglobulin G4-related lung disease: clinicoradiological and pathological features. Respirology. 2013;18:480–7.PubMed
76.
Nakazawa T, Ohara H, Sano H, et al. Schematic classification of sclerosing cholangitis with autoimmune pancreatitis by cholangiography. Pancreas. 2006;32:229.PubMed
77.
Nakazawa T, Ohara H, Sano H, et al. Clinical differences between primary sclerosing cholangitis and sclerosing cholangitis with autoimmune pancreatitis. Pancreas. 2005;30:20–5.PubMed
78.
Nishino T, Oyama H, Hashimoto E, et al. Clinicopathological differentiation between sclerosing cholangitis with autoimmune pancreatitis and primary sclerosing cholangitis. J Gastroenterol. 2007;42:550–9.PubMed
79.
Hamano H, Kawa S, Uehara T, et al. Immunoglobulin G4-related lymphoplasmacytic sclerosing cholangitis that mimics infiltrating hilar cholangiocarcinoma: part of a spectrum of autoimmune pancreatitis? Gastrointest Endosc. 2005;62:152–7.PubMed
80.
Hayashi K, Nakazawa T, Ohara H, et al. Autoimmune sclerosing cholangiopancreatitis with little pancreatic involvements by imaging findings. Hepatogastroenterology. 2007;54:2146–51.PubMed
81.
Naitoh I, Nakazawa T, Ohara H, et al. Endoscopic transpapillary intraductal ultrasonography and biopsy in the diagnosis of IgG4-related sclerosing cholangitis. J Gastroenterol. 2009;44:1147–55.PubMed
82.
Ohara H, Okazaki K, Tsubouchi H, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci. 2012;19:536–42.PubMed
83.
Kamisawa T, Nakazawa T, Tazuma S, et al. Clinical practice guidelines for IgG4-related sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2019;26:9–42.PubMedPubMedCentral
84.
Naitoh I, Zen Y, Nakazawa T, et al. Small bile duct involvement in IgG4-related sclerosing cholangitis: liver biopsy and cholangiography correlation. J Gastroenterol. 2011;46:269–76.PubMed
85.
Kuwatani M, Kawakami H, Zen Y, et al. Difference from bile duct cancer and relationship between bile duct wall thickness and serum IgG/IgG4 levels in IgG4-related sclerosing cholangitis. Hepatogastroenterology. 2014;61:1852–6.PubMed
86.
Hirano K, Tada M, Isayama H, et al. Endoscopic evaluation of factors contributing to intrapancreatic biliary stricture in autoimmune pancreatitis. Gastrointest Endosc. 2010;71:85–90.PubMed
87.
Watanabe T, Maruyama M, Ito T, et al. Mechanisms of lower bile duct stricture in autoimmune pancreatitis. Pancreas. 2014;43:255–60.PubMed
88.
Kubota K, Kato S, Uchiyama T, et al. Discrimination between sclerosing cholangitis-associated autoimmune pancreatitis and primary sclerosing cholangitis, cancer using intraductal ultrasonography. Dig Endosc. 2011;23:10–6.PubMed
89.
Naitoh I, Nakazawa T, Hayashi K, et al. Comparison of intraductal ultrasonography findings between primary sclerosing cholangitis and IgG4-related sclerosing cholangitis. J Gastroenterol Hepatol. 2015;30:1104–9.PubMed
90.
Zen Y, Onodera M, Inoue D, et al. Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol. 2009;33:1833–9.PubMed
91.
Otsuka H, Morita N, Yamashita K, et al. FDG-PET/CT findings of autoimmune pancreatitis associated with idiopathic retroperitoneal fibrosis. Ann Nucl Med. 2007;21:593–6.PubMed
92.
Kuwatani M, Kawakami H, Makiyama H, et al. Autoimmune pancreatitis with retroperitoneal fibrosis which responded to steroid therapy but was complicated with refractory renal dysfunction. Intern Med. 2007;46:1557–64.PubMed
93.
Raissian Y, Nasr SH, Larsen CP, et al. Diagnosis of IgG4-related tubulointerstitial nephritis. J Am Soc Nephrol. 2011;22:1343–52.PubMedPubMedCentral
94.
Kawano M, Saeki T, Nakashima H, et al. Proposal for diagnostic criteria for IgG4-related kidney disease. Clin Exp Nephrol. 2011;15:615–26.PubMed
95.
Saeki T, Saito A, Yamazaki H, et al. Tubulointerstitial nephritis associated with IgG4-related systemic disease. Clin Exp Nephrol. 2007;11:168–73.PubMed
96.
Saeki T, Nishi S, Imai N, et al. Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney Int. 2010;78:1016–23.PubMed
97.
Saeki T, Imai N, Ito T, et al. Membranous nephropathy associated with IgG4-related systemic disease and without autoimmune pancreatitis. Clin Nephrol. 2009;71:173–8.PubMed
98.
Kasashima S, Zen Y, Kawashima A, et al. A clinicopathologic study of immunoglobulin G4-related sclerosing disease of the thoracic aorta. J Vasc Surg. 2010;52:1587–95.PubMed
99.
Matsumoto Y, Kasashima S, Kawashima A, et al. A case of multiple immunoglobulin G4-related periarteritis: a tumorous lesion of the coronary artery and abdominal aortic aneurysm. Hum Pathol. 2008;39:975–80.PubMed
100.
Mizushima I, Kasashima S, Fujinaga Y, et al. Clinical and pathological characteristics of IgG4-related periaortitis/periarteritis and retroperitoneal fibrosis diagnosed based on experts’ diagnosis. Ann Vasc Dis. 2019;12:460–72.PubMedPubMedCentral
101.
Ozawa M, Fujinaga Y, Asano J, et al. Clinical features of IgG4-related periaortitis/periarteritis based on the analysis of 179 patients with IgG4-related disease: a case-control study. In: Arthritis Res Ther. vol. 19, 2017/10/06 edn; 2017: 223.
102.
Kasashima S, Zen Y, Kawashima A, et al. A new clinicopathological entity of IgG4-related inflammatory abdominal aortic aneurysm. J Vasc Surg. 2009;49:1264–71.PubMed
103.
Tajima M, Hiroi Y, Takazawa Y, et al. Immunoglobulin G4-related multiple systemic aneurysms and splenic aneurysm rupture during steroid therapy. Hum Pathol. 2014;45:175–9.PubMed
104.
Mizushima I, Inoue D, Yamamoto M, et al. Clinical course after corticosteroid therapy in IgG4-related aortitis/periaortitis and periarteritis: a retrospective multicenter study. In: Arthritis Res Ther. vol. 16; 2014: R156.
105.
Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020;79:77–87.PubMed
106.
Ichikawa T, Sou H, Araki T, et al. Duct-penetrating sign at MRCP: usefulness for differentiating inflammatory pancreatic mass from pancreatic carcinomas. Radiology. 2001;221:107–16.PubMed
107.
Sugiyama Y, Fujinaga Y, Kadoya M, et al. Characteristic magnetic resonance features of focal autoimmune pancreatitis useful for differentiation from pancreatic cancer. Jpn J Radiol. 2012;30:296–309.PubMed
108.
Hur BY, Lee JM, Lee JE, et al. Magnetic resonance imaging findings of the mass-forming type of autoimmune pancreatitis: comparison with pancreatic adenocarcinoma. J Magn Reson Imaging. 2012;36:188–97.PubMed
109.
Kamisawa T, Takuma K, Anjiki H, et al. Differentiation of autoimmune pancreatitis from pancreatic cancer by diffusion-weighted MRI. Am J Gastroenterol. 2010;105:1870–5.PubMed
110.
Muhi A, Ichikawa T, Motosugi U, et al. Mass-forming autoimmune pancreatitis and pancreatic carcinoma: differential diagnosis on the basis of computed tomography and magnetic resonance cholangiopancreatography, and diffusion-weighted imaging findings. J Magn Reson Imaging. 2012;35:827–36.PubMed
111.
Hoki N, Mizuno N, Sawaki A, et al. Diagnosis of autoimmune pancreatitis using endoscopic ultrasonography. J Gastroenterol. 2009;44:154–9.PubMed
112.
Okabe Y, Ishida Y, Kaji R, et al. Endoscopic ultrasonographic study of autoimmune pancreatitis and the effect of steroid therapy. J Hepatobiliary Pancreat Sci. 2012;19:266–73.PubMed
113.
Yoshinaga S, Itoi T, Yamao K, et al. Safety and efficacy of endoscopic ultrasound-guided fine needle aspiration for pancreatic masses: A prospective multicenter study. Dig Endosc. 2010;32:114–26.
114.
Dhall D, Suriawinata AA, Tang LH, Shia J, Klimstra DS. Use of immunohistochemistry for IgG4 in the distinction of autoimmune pancreatitis from peritumoral pancreatitis. Hum Pathol. 2010;41:643–52.PubMed
115.
Uehara T, Hamano H, Kawa S, Kobayashi Y, Yoshizawa A, Oki K, et al. Comparison of histopathological features of pancreatic carcinoma and type 1 autoimmune pancreatitis. Pathol Int. 2014;64:51–7.PubMed
116.
Witkiewicz AK, Kennedy EP, Kennyon L, et al. Synchronous autoimmune pancreatitis and infiltrating pancreatic ductal adenocarcinoma: case report and review of the literature. Hum Pathol. 2008;39:1548–51.PubMed
117.
Motosugi U, Ichikawa T, Yamaguchi H, et al. Small invasive ductal adenocarcinoma of the pancreas associated with lymphoplasmacytic sclerosing pancreatitis. Pathol Int. 2009;2009(59):744–7.
118.
Kamisawa T, Yoshiike M, Egawa N, et al. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study. Pancreatology. 2005;5:234–40.PubMed
119.
Kubota K, Iida H, Fujisawa T, et al. Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc. 2007;66:1142–51.PubMed
120.
Kubota K, Watanabe S, Uchiyama T, et al. Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids. J Gastroenterol. 2011;46:834–42.PubMed
121.
Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58:1504–7.PubMed
122.
Hart PA, Kamisawa T, Brugge WR, et al. Long-term outcomes of autoimmune pancreatitis: a multicenter, international analysis. Gut. 2013;62:1771–6.PubMed
123.
Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015;67:1688–99.PubMed
124.
Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. 2013;62:1607–15.PubMed
125.
Kubota K, Kamisawa T, Okazaki K, et al. Low-dose maintenance steroid treatment could reduce the relapse rate in patients with type 1 autoimmune pancreatitis: a long-term Japanese multicenter analysis of 510 patients. J Gastroenterol. 2017;52:955–64.PubMed
126.
Masamune A, Nishimori I, Kikuta K, et al. Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis. Gut. 2017;66:487–94.PubMed
127.
Tacelli M, Celsa C, Magro B, et al. Risk factors for rate of relapse and effects of steroid maintenance therapy in patients with autoimmune pancreatitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:1061–72.PubMed
128.
Okazaki K, Chari ST, Frulloni L, et al. International consensus for the treatment of autoimmune pancreatitis. Pancreatology. 2017;17:1–6.PubMed
129.
Hirano K, Tada M, Isayama H, et al. Outcome of long-term maintenance steroid therapy cessation in patients with autoimmune pancreatitis. A prospective study J Clin Gastroenterol. 2016;50:331–7.PubMed
130.
Nakamura A, Ozawa M, Watanabe T, et al. Predictive factors for autoimmune pancreatitis relapse after 3 years of maintenance therapy. Pancreas. 2018;47:1337–43.PubMed
131.
132.
Miyamoto Y, Kamisawa T, Tabata T, et al. Short and long-term outcomes of diabetes mellitus in patients with autoimmune pancreatitis after steroid therapy. Gut Liver. 2012;6:501–4.PubMedPubMedCentral
133.
Ikeura T, Miyoshi H, Uchida K, et al. Relationship between autoimmune pancreatitis and pancreatic cancer: A single-center experience. Pancreatology. 2014;14:373–9.PubMed
134.
Lee HW, Moon SH, Kim MH, et al. Relapse rate and predictors of relapse in a large single center cohort of type 1 autoimmune pancreatitis: long-term follow-up results after steroid therapy with short-duration maintenance treatment. J Gastroenterol. 2018;53:967–77.PubMed
135.
Matsumori T, Shiokawa M, Kodama Y. Pancreas mass in a patient with an increased serum level of IgG4. Gastroenterology. 2018;155:269–70.PubMed
136.
Shiokawa M, Kodama Y, Chiba T, et al. Risk of cancer in patients with autoimmune pancreatitis. Am J Gastroenterol. 2013;108:610–7.PubMed
Metadata
Title
Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2020
Authors
Kazuichi Okazaki
Shigeyuki Kawa
Terumi Kamisawa
Tsukasa Ikeura
Takao Itoi
Tetsuhide Ito
Kazuo Inui
Atsushi Irisawa
Kazushige Uchida
Hirotaka Ohara
Kensuke Kubota
Yuzo Kodama
Kyoko Shimizu
Ryosuke Tonozuka
Takahiro Nakazawa
Takayoshi Nishino
Kenji Notohara
Yasunari Fujinaga
Atsushi Masamune
Hiroshi Yamamoto
Takayuki Watanabe
Toshimasa Nishiyama
Mitsuhiro Kawano
Keiko Shiratori
Tooru Shimosegawa
Yoshifumi Takeyama
Members of the Research Committee for IgG4-related Disease supported by the Ministry of Health, Labour, Welfare of Japan, Japan Pancreas Society
Publication date
01-04-2022
Publisher
Springer Singapore
Published in
Journal of Gastroenterology / Issue 4/2022
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-022-01857-9

Other articles of this Issue 4/2022

Journal of Gastroenterology 4/2022 Go to the issue

Original Article—Liver, Pancreas, and Biliary Tract

The useful predictors of zinc deficiency for the management of chronic liver disease

Review

A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation

Original Article—Alimentary Tract

Colorectal carcinoma occurring via the adenoma–carcinoma pathway in patients with serrated polyposis syndrome

Original Article—Alimentary Tract

Clinicopathological characteristics of colorectal serrated polyposis syndrome (SPS): results of a multicenter study by the SPS Study Group in Japan

Original Article—Liver, Pancreas, and Biliary Tract

Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts

Review Article

Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits